ATLANTA--(BUSINESS WIRE)--Speaking today at the JPMorgan Healthcare Conference in San Francisco; Patrick Fourteau, President and Chief Executive Officer of Sciele Pharma, Inc. (NASDAQ:SCRX), raised the Company’s revenue guidance for full-year 2006 to between $290 million and $292 million from the previously announced range of $287 million to $290 million, and raised the earnings guidance to between $1.18 and $1.20 per share from the previously announced range of $1.16 to $1.19 per share. Mr. Fourteau also reaffirmed the Company’s previously announced full-year 2007 revenue guidance of $335 million to $350 million and diluted earnings per share guidance of $1.53 to $1.62.
